Compositions and Methods for Detecting C1orf43 Nucleic Acid
AssigneeGen-Probe Incorporated
InventorsSiobhán M. Miick, Paul M. Darby, Jo Ann Jackson, Damon Kittredge Getman
Life of this patent
Estimating the term…
Abstract
This disclosure provides oligomers, combinations of oligomers, compositions, kits, uses, and methods for detecting a C1orf43 nucleic acid, such as C1orf43 mRNA, such as human C1orf43 mRNA, in a sample.
Claims140
A combination of oligomers comprising at least first and second amplification oligomers, wherein the first and second amplification oligomers are reverse and forward amplification oligomers, respectively;
- each comprise at least 10 nucleotides;
- and are configured to specifically hybridize to first and second sites in the sequence of SEQ ID NO:
- 39 and generate an amplicon therefrom, respectively.
A method of detecting the presence or absence of a C1orf43 nucleic acid in a sample, comprising:
- contacting the sample with a combination of oligomers comprising at least first and second amplification oligomers,
- performing a nucleic acid amplification reaction which produces at least a first amplicon in the presence of the C1orf43 nucleic acid,
- and detecting the presence or absence of the first amplicon,
- wherein:
- the first amplicon is produced through extension of the first and second amplification oligomers in the presence of the C1orf43 nucleic acid;
- and
- wherein the first and second amplification oligomers are reverse and forward amplification oligomers, respectively;
- each comprise at least 10 nucleotides;
- and are configured to specifically hybridize to first and second sites in the sequence of SEQ ID NO:
- 39, respectively.
The combination or method of any one of the preceding claims, wherein the first amplification oligomer is a promoter-primer.
The combination or method of any one of the preceding claims, wherein the first and second amplification oligomer are configured to generate an amplicon comprising at least 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 144 nucleotides of the sequence of SEQ ID NO:
- 40.
The combination or method of any one of the preceding claims, wherein the first amplification oligomer is configured to specifically hybridize to a first site in the complement of SEQ ID NO:
- 52.
The combination or method of any one of the preceding claims, wherein the first amplification oligomer comprises a target-hybridizing sequence comprising the sequence of SEQ ID NO:
- 27, optionally with up to two mismatches.
The combination or method of any one of the preceding claims, wherein the first amplification oligomer comprises a target-hybridizing sequence comprising the sequence of SEQ ID NO:
- 27, 29, 31, or 33.
The combination or method of any one of the preceding claims, wherein the first amplification oligomer comprises the sequence of SEQ ID NO:
- 26, 28, 30, or 32.
The combination or method of any one of the preceding claims, wherein the second amplification oligomer is configured to specifically hybridize to a second site in the complement of SEQ ID NO:
- 46.
The combination or method of any one of the preceding claims, wherein the second amplification oligomer comprises a target-hybridizing sequence comprising the sequence of SEQ ID NO:
- 34, optionally with up to two mismatches.
The combination or method of any one of the preceding claims, wherein the second amplification oligomer comprises a target-hybridizing sequence comprising the sequence of SEQ ID NO:
- 34, 35, 36, 37, or 38.
The combination or method of any one of the preceding claims, wherein the combination further comprises at least one probe oligomer that comprises at least 10 nucleotides and is configured to specifically hybridize to an amplicon produced from the first and second amplification oligomers.
A probe oligomer that comprises at least 10 nucleotides and is configured to specifically hybridize to a detection site in a nucleic acid having the sequence of SEQ ID NO:
- 43.
A probe oligomer that comprises a target hybridizing sequence comprising the sequence of any one of SEQ ID NO:
- 61, 62, 63, or 65 with up to two mismatches
A method of isolating C1orf43 nucleic acid from a sample, comprising:
- contacting the sample with at least one capture oligomer under conditions permissive for forming one or more complexes of a capture oligomer and the C1orf43 nucleic acid, thereby forming a composition, wherein the capture oligomer comprises at least 10 nucleotides and is configured to specifically hybridize to a capture site in the sequence of SEQ ID NO:
- 39;
- and
- isolating the capture oligomer from the composition.
A capture oligomer that comprises at least 10 nucleotides and is configured to specifically hybridize to a capture site in the sequence of SEQ ID NO:
- 39.
A kit or composition comprising at least one, two, three, or four of a first amplification oligomer, a second amplification oligomer, a probe oligomer, or a capture oligomer recited in any one of the preceding claims.
Use of the combination, method, composition, capture oligomer, probe oligomer, or kit of any one of the preceding claims for detecting the presence or absence of a C1orf43 nucleic acid in a sample.
Dependencies are inferred from the claim text.